Hikma Pharmaceuticals (HIK) Competitors

Hikma Pharmaceuticals (LON:HIK) and HUTCHMED (LON:HCM) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation.

Which has more volatility & risk, HIK or HCM?

Hikma Pharmaceuticals has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500. Comparatively, HUTCHMED has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500.

Which has better valuation & earnings, HIK or HCM?

Hikma Pharmaceuticals has higher revenue and earnings than HUTCHMED. HUTCHMED is trading at a lower price-to-earnings ratio than Hikma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hikma Pharmaceuticals	£3.22B	1.12	£353.21M	£1.67	977.25
HUTCHMED	£602.20M	3.71	-£52.98M	£0.53	490.57

Is HIK or HCM more profitable?

Hikma Pharmaceuticals has a net margin of 9.45% compared to HUTCHMED's net margin of -6.87%. Hikma Pharmaceuticals' return on equity of 12.71% beat HUTCHMED's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hikma Pharmaceuticals	9.45%	12.71%	9.40%
HUTCHMED	-6.87%	-5.71%	-5.90%

Does the media prefer HIK or HCM?

In the previous week, HUTCHMED had 1 more articles in the media than Hikma Pharmaceuticals. MarketBeat recorded 2 mentions for HUTCHMED and 1 mentions for Hikma Pharmaceuticals. HUTCHMED's average media sentiment score of 0.73 beat Hikma Pharmaceuticals' score of -1.04 indicating that HUTCHMED is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hikma Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative
HUTCHMED	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Do insiders & institutionals hold more shares of HIK or HCM?

63.6% of Hikma Pharmaceuticals shares are owned by institutional investors. Comparatively, 2.2% of HUTCHMED shares are owned by institutional investors. 17.8% of Hikma Pharmaceuticals shares are owned by company insiders. Comparatively, 2.8% of HUTCHMED shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Do analysts recommend HIK or HCM?

Hikma Pharmaceuticals currently has a consensus target price of GBX 2,627.50, suggesting a potential upside of 61.00%. Given Hikma Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Hikma Pharmaceuticals is more favorable than HUTCHMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hikma Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
HUTCHMED	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Hikma Pharmaceuticals beats HUTCHMED on 12 of the 16 factors compared between the two stocks.